Literature DB >> 3511094

Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients.

K S Polonsky, J Licinio-Paixao, B D Given, W Pugh, P Rue, J Galloway, T Karrison, B Frank.   

Abstract

We undertook this study to examine the accuracy of plasma C-peptide as a marker of insulin secretion. The peripheral kinetics of biosynthetic human C-peptide (BHCP) were studied in 10 normal volunteers and 7 insulin-dependent diabetic patients. Each subject received intravenous bolus injections of BHCP as well as constant and variable rate infusions. After intravenous bolus injections the metabolic clearance rate of BHCP (3.8 +/- 0.1 ml/kg per min, mean +/- SEM) was not significantly different from the value obtained during its constant intravenous infusion (3.9 +/- 0.1 ml/kg per min). The metabolic clearance rate of C-peptide measured during steady state intravenous infusions was constant over a wide concentration range. During experiments in which BHCP was infused at a variable rate, the peripheral concentration of C-peptide did not change in proportion to the infusion rate. Thus, the infusion rate of BHCP could not be calculated accurately as the product of the C-peptide concentration and metabolic clearance rate. However, the non-steady infusion rate of BHCP could be accurately calculated from peripheral C-peptide concentrations using a two-compartment mathematical model when model parameters were derived from the C-peptide decay curve in each subject. Application of this model to predict constant infusions of C-peptide from peripheral C-peptide concentrations resulted in model generated estimates of the C-peptide infusion rate that were 101.5 +/- 3.4% and 100.4 +/- 2.8% of low and high dose rates, respectively. Estimates of the total quantity of C-peptide infused at a variable rate over 240 min based on the two-compartment model represented 104.6 +/- 2.4% of the amount actually infused. Application of this approach to clinical studies will allow the secretion rate of insulin to be estimated with considerable accuracy. The insulin secretion rate in normal subjects after an overnight fast was 89.1 pmol/min, which corresponds with a basal 24-h secretion of 18.6 U.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3511094      PMCID: PMC423314          DOI: 10.1172/JCI112308

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

Review 1.  Role of insulin in the hepatic handling of glucose.

Authors:  L L Madison
Journal:  Arch Intern Med       Date:  1969-03

2.  Kinetics of human connecting peptide in normal and diabetic subjects.

Authors:  O K Faber; C Hagen; C Binder; J Markussen; V K Naithani; P M Blix; H Kuzuya; D L Horwitz; A H Rubenstein; N Rossing
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

3.  Effect of intraduodenal glucose administration on hepatic extraction of insulin in the anesthetized dog.

Authors:  M Kaden; P Harding; J B Field
Journal:  J Clin Invest       Date:  1973-08       Impact factor: 14.808

4.  Factitious hypoglycemia. Diagnosis by measurement of serum C-peptide immunoreactivity and insulin-binding antibodies.

Authors:  J A Scarlett; M E Mako; A H Rubenstein; P M Blix; J Goldman; D L Horwitz; H Tager; J B Jaspan; M R Stjernholm; J M Olefsky
Journal:  N Engl J Med       Date:  1977-11-10       Impact factor: 91.245

5.  Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-etide response to intravenous glucagon.

Authors:  C Hendriksen; O K Faber; J Drejer; C Binder
Journal:  Diabetologia       Date:  1977-12       Impact factor: 10.122

6.  C-Peptide and insulin secretion in Pima Indians and Caucasians: constant fractional hepatic extraction over a wide range of insulin concentrations and in obesity.

Authors:  P J Savage; E V Flock; M E Mako; P M Blix; A H Rubenstein; P H Bennett
Journal:  J Clin Endocrinol Metab       Date:  1979-04       Impact factor: 5.958

7.  Insulin production rate, hepatic insulin retention and splanchnic carbohydrate metabolism after oral glucose ingestion in hyperinsulinaemic Type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  W Waldhäusl; P Bratusch-Marrain; S Gasić; A Korn; P Nowotny
Journal:  Diabetologia       Date:  1982-07       Impact factor: 10.122

8.  A model of the kinetics of insulin in man.

Authors:  R S Sherwin; K J Kramer; J D Tobin; P A Insel; J E Liljenquist; M Berman; R Andres
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

9.  Characterization of seven C-peptide antisera.

Authors:  O K Faber; C Binder; J Markussen; L G Heding; V K Naithani; H Kuzuya; P Blix; D L Horwitz; A H Rubenstein
Journal:  Diabetes       Date:  1978       Impact factor: 9.461

10.  Feedback inhibition by biosynthetic human insulin of insulin release in healthy human subjects.

Authors:  W K Waldhäusl; S Gasić; P Bratusch-Marrain; A Korn; P Nowotny
Journal:  Am J Physiol       Date:  1982-12
View more
  74 in total

1.  Automated chemiluminescent assay for C-peptide.

Authors:  R W Hardy; M Cohn; R J Konrad
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  A model of GLP-1 action on insulin secretion in nondiabetic subjects.

Authors:  Chiara Dalla Man; Francesco Micheletto; Airani Sathananthan; Robert A Rizza; Adrian Vella; Claudio Cobelli
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-02-23       Impact factor: 4.310

3.  Studies on the mechanism of action of sulphonylureas in type II diabetic subjects: gliquidone.

Authors:  E Bonora; P Moghetti; M Querena; M Zenere; V Cacciatori; F Tosi; D Travia; G Zoppini; M Muggeo
Journal:  J Endocrinol Invest       Date:  1992-01       Impact factor: 4.256

4.  Heritability of model-derived parameters of beta cell secretion during intravenous and oral glucose tolerance tests: a study of twins.

Authors:  M Lehtovirta; J Kaprio; L Groop; M Trombetta; R C Bonadonna
Journal:  Diabetologia       Date:  2005-06-24       Impact factor: 10.122

5.  Abnormalities in the ultradian oscillations of insulin secretion and glucose levels in type 2 (non-insulin-dependent) diabetic patients.

Authors:  J Sturis; K S Polonsky; E T Shapiro; J D Blackman; N M O'Meara; E van Cauter
Journal:  Diabetologia       Date:  1992-07       Impact factor: 10.122

6.  24-hour glucose profiles during continuous or oscillatory insulin infusion. Demonstration of the functional significance of ultradian insulin oscillations.

Authors:  J Sturis; A J Scheen; R Leproult; K S Polonsky; E van Cauter
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Twenty-four hour insulin secretion and beta cell NEFA oxidation in type 2 diabetic, morbidly obese patients before and after bariatric surgery.

Authors:  S Salinari; A Bertuzzi; A Iaconelli; M Manco; G Mingrone
Journal:  Diabetologia       Date:  2008-05-06       Impact factor: 10.122

Review 8.  Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

Authors:  Cornelia B Landersdorfer; William J Jusko
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

9.  Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients.

Authors:  Gilberto Paz-Filho; Karin Esposito; Barry Hurwitz; Anil Sharma; Chuanhui Dong; Victor Andreev; Tuncay Delibasi; Halil Erol; Alejandro Ayala; Ma-Li Wong; Julio Licinio
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-10-14       Impact factor: 4.310

10.  The influence of human C-peptide on renal function and glucose utilization in type 1 (insulin-dependent) diabetic patients.

Authors:  B L Johansson; S Sjöberg; J Wahren
Journal:  Diabetologia       Date:  1992-02       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.